Newsroom News May 5, 2022 The latest argenx Reports First Quarter 2022 Financial Results and Provides Business Update Breda, the Netherlands argenx today reported financial results for the first quarter 2022 and provided a business update. Read argenx Stories See where we started — and where we’re going — as we chart a new course together in immunology. argenx Stories Interested in Learning More? Get argenx news and updates right to your inbox Subscribe Past Press Releases May 19, 2022 argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases May 10, 2022 argenx announces results of Annual General Meeting of Shareholders May 5, 2022 argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia May 4, 2022 argenx to Present at BofA Securities 2022 Healthcare Conference More Press Releases Download assets Get photos, fact sheets, illustrations and more. Download now Join the team Dare to do more with a thriving career at Argenx. Find your career Follow us Get the latest news and info via our social media channels.